The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Bronchiectasis: new therapies and new perspectives
Open accessAbstract
European Respiratory Society guidelines for the management of adult bronchiectasis highlight the paucity of treatment options available for patients with this disorder. No treatments have been licensed by regulatory agencies worldwide, and most therapies used in clinical practice are based on very little evidence. Development of new treatments is needed urgently. We did a systematic review of scientific literature and clinical trial registries to identify agents in early-to-late clinical development for bronchiectasis in adults. In this Review, we discuss the mechanisms and potential roles of emerging therapies, including drugs that target airway and systemic inflammation, mucociliary clearance, and epithelial dysfunction. To ensure these treatments achieve success in randomised clinical trials-and therefore reach patients-we propose a reassessment of the current approach to bronchiectasis. Although understanding of the pathophysiology of bronchiectasis is at an early stage, we argue that bronchiectasis is a heterogeneous disease with many different biological mechanisms that drive disease progression (endotypes), and therefore the so-called treatable traits approach used in asthma and chronic obstructive pulmonary disease could be applied to bronchiectasis, with future trials targeted at the specific disease subgroups most likely to benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The bronchiectasis severity index. An international derivation and validation study
Chalmers, J. D., Goeminne, P., Aliberti, S., McDonnell, M. J., Lonni, S., Davidson, J., Poppelwell, L., Salih, W., Pesci, A., Dupont, L. J., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1575oc · Cited by 1,093
Self-citationWong, C., Jayaram, L., Karalus, N., Eaton, T., Tong, C., Hockey, H., Milne, D., Fergusson, W., Tuffery, C., Sexton, P., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60953-2 · Cited by 600
A novel microbiota stratification system predicts future exacerbations in bronchiectasis
Rogers, G. B., Zain, N. M. M., Bruce, K. D., Burr, L. D., Chen, A. C., Rivett, D. W., McGuckin, M. A., & Serisier, D. J. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201310-335oc · Cited by 244
SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects
Holz, O., Khalilieh, S., Ludwig-Sengpiel, A., Watz, H., Stryszak, P., Soni, P., Tsai, M., Sadeh, J., & Magnussen, H. (2010) · European Respiratory Journal · doi:10.1183/09031936.00048509 · Cited by 183
Cited by
Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity
Flume, P. A., Chalmers, J. D., & Olivier, K. N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31767-7 · Cited by 545
Self-citationPhase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
Chalmers, J. D., Haworth, C. S., Metersky, M. L., Loebinger, M. R., Blasi, F., Sibila, O., O’Donnell, A. E., Sullivan, E. J., Mange, K. C., Fernandez, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021713 · Cited by 377
Self-citationChalmers, J. D., Chang, A. B., Chotirmall, S. H., Dhar, R., & McShane, P. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0042-3 · Cited by 351
Self-citationChalmers, J. D., Polverino, E., Crichton, M. L., Ringshausen, F. C., De Soyza, A., Vendrell, M., Burgel, P. R., Haworth, C. S., Loebinger, M. R., Dimakou, K., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00093-0 · Cited by 315
Self-citationBronchiectasis in children: diagnosis and treatment
Chang, A. B., Bush, A., & Grimwood, K. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31554-x · Cited by 276
Metadata
- Authors
- Chalmers, J. D., & Chotirmall, S. H.
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 6
- Issue
- 9
- Pages
- 715-726
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W2788969512
- Cited by
- 211
- References
- 4
- FWCI
- 17.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bronchiectasis: new therapies and new perspectives. https://app.cochat.ai/papers/10.1016/s2213-2600(18)30053-5
- The paper
- Chalmers, J. D., & Chotirmall, S. H. (2018). Bronchiectasis: new therapies and new perspectives. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(18)30053-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.